RFC
AEGR

Russell Frank Company’s Aegerion Pharmaceuticals AEGR Stock Holding History

Russell Frank Company’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-6,438
Closed -$66K – 3118
2015
Q4 		$66K Buy
+6,438
New +$77.5K ﹤0.01% 2857
2014
Q1 		– Sell
-29,129
Closed -$1.71M – 2942
2013
Q4 		$1.71M Sell
29,129
-22,541
-44% -$1.72M ﹤0.01% 1813
2013
Q3 		$4.43M Sell
51,670
-11,737
-19% -$995K 0.01% 1401
2013
Q2 		$4.02M Buy
+63,407
New +$3.37M 0.01% 1364

Other funds holding AEGR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Russell Frank Company's AEGR Position: Q1 2016 in Review

Russell Frank Company sold out of Aegerion Pharmaceuticals (AEGR) in Q1 2016, closing a stake of 6,438 shares — an estimated $66K sold.

Russell Frank Company first reported a position in AEGR in Q2 2013 and held it in 4 quarters. The position peaked at $4.43M in Q3 2013. 101 funds tracked by Wall St. Rank hold AEGR as of Q1 2016.

  • Russell Frank Company reported no remaining Aegerion Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Russell Frank Company sold 6,438 Aegerion Pharmaceuticals shares in Q1 2016, an estimated $66K.
  • Russell Frank Company first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 4 quarters.
  • Russell Frank Company's Aegerion Pharmaceuticals position peaked at $4.43M in Q3 2013.
  • 101 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q1 2016.

Based on Russell Frank Company's 13F filing for Q1 2016, filed 29 Apr 2016.